You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Amgen

Showing 26 - 50 of 1,427
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Patient ExperiEnce in the Real-World Setting

Recruiting
  • Lung Cancer Patients
  • Caregivers
  • There are no interventions in this study. All participants complete online surveys.
  • Bethesda, Maryland
    LUNGevity Foundation
Apr 26, 2023

Multiple Myeloma Trial in Detroit, Charlotte (Carfilzomib, Ruxolitinib, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Detroit, Michigan
  • +1 more
Jan 27, 2023

Ischemic Stroke Trial in Los Angeles (Repatha)

Terminated
  • Ischemic Stroke
  • Los Angeles, California
    UCLA
Jan 24, 2022

Immune Thrombocytopenia Trial in Jena

Recruiting
  • Immune Thrombocytopenia
    • Jena, Germany
      University Hospital Jena
    Mar 29, 2022

    Facial Pain, Rhinosinusitis Trial in Durham (Erenumab Prefilled Syringe, Placebo)

    Recruiting
    • Facial Pain
    • Rhinosinusitis
    • Erenumab Prefilled Syringe
    • Placebo
    • Durham, North Carolina
      Duke University Medical Center and affiliated practices
    Jun 23, 2022

    Non-Hodgkin Lymphoma Trial in Milano (Romiplostim)

    Completed
    • Non-Hodgkin Lymphoma
    • Milano, Italy
      Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte T
    Aug 10, 2022

    RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

    Recruiting
    • Nsclc
    • KRAS P.G12C
      • Paris, France
      • +2 more
      Aug 9, 2022

      Hematopoietic/Lymphoid Cancer, Richter's Transformation Trial in Houston (Blinatumomab, Dexamethasone)

      Completed
      • Hematopoietic/Lymphoid Cancer
      • Richter's Transformation
      • Houston, Texas
        University of Texas MD Anderson Cancer Center
      Mar 3, 2022

      Soft Tissue Sarcoma Trial in Iowa City (Talimogene Laherparepvec, Radiotherapy)

      Active, not recruiting
      Has Results
      • Soft Tissue Sarcoma
      • Talimogene Laherparepvec
      • Radiotherapy
      • Iowa City, Iowa
        University of Iowa Hospitals and Clinics
      May 4, 2022

      Melanoma Stage Iii, Melanoma Stage Iv, Melanoma Trial in Chapel Hill (Denosumab, Pembrolizumab, Nivolumab)

      Active, not recruiting
      • Melanoma Stage Iii
      • +4 more
      • Chapel Hill, North Carolina
        UNC Lineberger Comprehensive Cancer Center
      Jul 20, 2022

      Dyslipidemia in Patients at High Risk and Very High Risk of

      Recruiting
      • Secondary Prevention
      • +2 more
      • application
      • Leon, Guanajuato, Mexico
        Umae Cmn T1
      Sep 13, 2022

      Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma Trial in Tampa (Talimogene laherparepvec, Paclitaxel)

      Active, not recruiting
      Has Results
      • Breast Cancer
      • +3 more
      • Tampa, Florida
        H. Lee Moffitt Cancer Center and Research Institute
      Nov 10, 2022

      Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma Trial in Stanford, New York (Talimogene Laherparepvec (T-VEC),

      Recruiting
      • Sarcoma
      • +2 more
      • Stanford, California
      • +1 more
      Feb 2, 2023

      Acute Lymphoid Leukemia Trial in Seoul (Blincyto)

      Not yet recruiting
      • Acute Lymphoid Leukemia
      • Seoul, Gangnam-gu, Korea, Republic of
      • +4 more
      Apr 12, 2023

      Pharmacodynamics, Pharmacokinetics, Bioequivalence Trial in Yaroslavl (GP40141, Nplate)

      Recruiting
      • Pharmacodynamics
      • +2 more
      • Yaroslavl, Russian Federation
        Yaroslavl Region "Clinical Hospital No. 3", ,, Mayakovskogo st.,
      Dec 14, 2022

      Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia Trial in Yongin (Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg)

      Recruiting
      • Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
      • Evolocumab 140 MG/ML
      • +2 more
      • Yongin, Gyeonggi-do, Korea, Republic of
        Yongcheol Kim
      Jan 6, 2023

      Low Bone Density Trial in Toronto (Opportunistic screening for low BMD)

      Not yet recruiting
      • Low Bone Density
      • Opportunistic screening for low BMD
      • Toronto, Ontario, Canada
      • +1 more
      Jul 13, 2022

      Breast Cancer Trial in Barcelona, Madrid, Valencia (Talimogene laherparepvec, Atezolizumab)

      Active, not recruiting
      • Breast Cancer
      • Barcelona, Spain
      • +3 more
      Sep 27, 2022

      Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using

      Active, not recruiting
      • Non Small Cell Lung Cancer
      • therascreen® KRAS RGQ PCR Kit
      • Manchester, United Kingdom
        QIAGEN Gaithersburg, Inc
      Sep 26, 2022

      Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)

      Completed
      Has Results
      • Breast Cancer
      • Houston, Texas
        University of Texas MD Anderson Cancer Center
      Sep 20, 2022

      Symptomatic Anemia Trial in Zuidlaren (DA3880, Aranesp)

      Completed
      • Symptomatic Anemia
      • Zuidlaren, Netherlands
        PRA
      Jun 13, 2021

      First Progression of MGMT Promoter-methylated Glioblastoma Trial in Bellinzona, Zürich (Lomustine, Romiplostim)

      Recruiting
      • First Progression of MGMT Promoter-methylated Glioblastoma
      • Barcelona, Spain
      • +4 more
      Nov 16, 2022

      Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive Trial in New York (Blinatumomab, dasatinib, dexamethasone)

      Recruiting
      • Acute Lymphoblastic Leukemia
      • Philadelphia Chromosome-Positive
      • Blinatumomab
      • +3 more
      • New York, New York
      • +1 more
      Nov 10, 2022

      B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia

      Recruiting
      • B-cell Acute Lymphoblastic Leukemia
      • +2 more
      • Milwaukee, Wisconsin
        Medical College of Wisconsin
      Apr 4, 2022

      Acute Coronary Syndrome Trial in Baltimore (Evolocumab, Placebo)

      Active, not recruiting
      • Acute Coronary Syndrome
      • Baltimore, Maryland
        Steven Paul Schulman
      Jan 19, 2022